Literature DB >> 14946332

Transitory appearance of type 2 neutralizing antibody in patients infected with type 1 poliomyelitis virus.

A B SABIN.   

Abstract

Neutralizing antibodies for Type 2 (Lansing) poliomyelitis virus were tested periodically in a group of 18 patients from whom Type 1 poliomyelitis virus was recovered. Data for homotypic neutralizing antibodies and Type 2 complement-fixing antibodies were also available on the majority of these patients. The results indicated that Type 2 neutralizing antibodies first appeared or significantly increased in titer in 11 of the 18 patients during the first 2 to 4 weeks after onset. In most patients the Type 2 neutralizing antibody either completely disappeared at 3 months (in one patient between 2 and 4 weeks) or dropped in titer, while the Type 1 or homotypic antibody persisted in high titer. These results are interpreted as indicating that the Type 1 and Type 2 poliomyelitis viruses share a common antigen, and that the heterotypic anti-body response is transitory while the homotypic neutralizing antibody persists for a longer time.

Entities:  

Keywords:  POLIOMYELITIS

Mesh:

Substances:

Year:  1952        PMID: 14946332      PMCID: PMC2136122          DOI: 10.1084/jem.96.1.99

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  9 in total

1.  Serum neutralizing antibodies to the infecting strain of virus in poliomyelitis patients.

Authors:  W M HAMMON; E C ROBERTS
Journal:  Proc Soc Exp Biol Med       Date:  1948-11

2.  Preparation of specific complement-fixing antigens from the three prototypes of poliomyelitis viruses.

Authors:  M POLLARD; C M HSIANG; G R SHARP
Journal:  Proc Soc Exp Biol Med       Date:  1952-01

3.  Complement-fixation test for the Lansing strain of poliomyelitis virus.

Authors:  O LAHELLE
Journal:  Am J Hyg       Date:  1951-11

4.  Complement fixation with Brunhilde and Lansing poliomyelitis viruses propagated in tissue culture.

Authors:  A SVEDMYR; J F ENDERS; A HOLLOWAY
Journal:  Proc Soc Exp Biol Med       Date:  1952-02

5.  Poliomyelitis in Canadian Eskimos, laboratory studies. II.

Authors:  E M CLARK; A J RHODES
Journal:  Can J Med Sci       Date:  1951-08

6.  Age incidence and seasonal development of neutralizing antibodies to lansing poliomyelitis virus.

Authors:  T B TURNER; D H HOLLANDER; S BUCKLEY; U P KOKKO; C P WINSOR
Journal:  Am J Hyg       Date:  1950-11

7.  Development, persistence, and significance of type 2, poliomyelitis complement-fixing antibody in man.

Authors:  J CASALS; P K OLITSKY; A B SABIN
Journal:  J Exp Med       Date:  1952-07       Impact factor: 14.307

8.  Antibody response of patients with poliomyelitis to virus recovered from their own alimentary tract.

Authors:  A J STEIGMAN; A B SABIN
Journal:  J Exp Med       Date:  1949-10       Impact factor: 14.307

9.  A specific complement-fixation test for infection with poliomyelitis virus.

Authors:  J CASALS; P K OLITSKY; R O ANSLOW
Journal:  J Exp Med       Date:  1951-08       Impact factor: 14.307

  9 in total
  18 in total

1.  Prevalence of poliomyelitis neutralizing antibodies in Norwegian school children before vaccination.

Authors:  J C ULSTRUP; R MEMMER
Journal:  Arch Gesamte Virusforsch       Date:  1959

2.  A survey of poliovirus neutralizing antibody in Newfoundland, 1959-60.

Authors:  R L OZERE; K R ROZEE
Journal:  Can Med Assoc J       Date:  1961-07-08       Impact factor: 8.262

3.  The development of homologous neutralizing antibody during a type 1 poliomyelitis epidemic.

Authors:  J A MILES; F J AUSTIN; J E CAUGHEY
Journal:  J Hyg (Lond)       Date:  1958-09

4.  The immune status of a population at the termination of a severe epidemic of poliomyelitis.

Authors:  C A EVANS; V C CHAMBERS; W R GIEDT; A N WILSON
Journal:  J Hyg (Lond)       Date:  1957-06

5.  The incidence of infection among contacts of poliomyelitis cases.

Authors:  D M HORSTMANN; R W MCCOLLUM; A D MASCOLA
Journal:  J Clin Invest       Date:  1955-10       Impact factor: 14.808

6.  [Virus-caused diseases in otorhinolaryngology].

Authors:  A BECKER
Journal:  Arch Ohren Nasen Kehlkopfheilkd       Date:  1955-05-02

7.  Oral administration of a rodent-adapted strain of poliomyelitis virus to chimpanzees.

Authors:  H KOPROWSKI; G A JERVIS; T W NORTON
Journal:  Arch Gesamte Virusforsch       Date:  1954

8.  [Morphological principles for new opinions on the pathological picture of poliomyelitis].

Authors:  R GADEKE
Journal:  Virchows Arch Pathol Anat Physiol Klin Med       Date:  1952

9.  Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010.

Authors:  Jan Felix Drexler; Gilda Grard; Alexander N Lukashev; Liubov I Kozlovskaya; Sindy Böttcher; Gökhan Uslu; Johan Reimerink; Anatoly P Gmyl; Raphaël Taty-Taty; Sonia Etenna Lekana-Douki; Dieudonné Nkoghe; Anna M Eis-Hübinger; Sabine Diedrich; Marion Koopmans; Eric M Leroy; Christian Drosten
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

10.  Poliomyelitis: epidemiology and prophylaxis. 1. A longitudinal epidemiological survey in Kenya.

Authors:  B K Nottay; D Metselaar
Journal:  Bull World Health Organ       Date:  1973       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.